Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma

by Gonsalves, W I, Leung, N, Rajkumar, S V, Dispenzieri, A, Lacy, M Q, Hayman, S R, Buadi, F K, Dingli, D, Kapoor, P, Go, R S, Lin, Y, Russell, S J, Lust, J A, Zeldenrust, S, Kyle, R A, Gertz, M A, Kumar, S K
Published 2015

Phase I/II study of melphalan, prednisone and lenalidomide combination for patients with newly diagnosed multiple myeloma who are not candidates for stem cell transplantation

by Roy, V, Stewart, A K, Bergsagel, P L, Dispenzieri, A, Laumann, K, Allred, J, Lacy, M Q, Fonseca, R, Reeder, C B, Kumar, S, Rivera, C E, Gertz, M A, Buadi, F K, Hayman, S R, Rajkumar, S V
Published 2015

Occurrence and prognostic significance of cytogenetic evolution in patients with multiple myeloma

by Binder, M, Rajkumar, S V, Ketterling, R P, Dispenzieri, A, Lacy, M Q, Gertz, M A, Buadi, F K, Hayman, S R, Hwa, Y L, Zeldenrust, S R, Lust, J A, Russell, S J, Leung, N, Kapoor, P, Go, R S, Gonsalves, W I, Kyle, R A, Kumar, S K
Published 2016

Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib

by Kumar, S K, LaPlant, B, Roy, V, Reeder, C B, Lacy, M Q, Gertz, M A, Laumann, K, Thompson, M A, Witzig, T E, Buadi, F K, Rivera, C E, Mikhael, J R, Bergsagel, P L, Kapoor, P, Hwa, L, Fonseca, R, Stewart, A K, Chanan-Khan, A, Rajkumar, S V, Dispenzieri, A
Published 2015

Abnormal FISH in patients with immunoglobulin light chain amyloidosis is a risk factor for cardiac involvement and for death

by Warsame, R, Kumar, S K, Gertz, M A, Lacy, M Q, Buadi, F K, Hayman, S R, Leung, N, Dingli, D, Lust, J A, Ketterling, R P, Lin, Y, Russell, S, Hwa, L, Kapoor, P, Go, R S, Zeldenrust, S R, Kyle, R A, Rajkumar, S V, Dispenzieri, A
Published 2015